This month several ProQRians will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer® RNA-editing platform technology.
Partnerships in our industry are very common as companies look to benefit from knowledge and resource sharing. In this blog we explore why companies, like ProQR, partner with other companies.
Today we are delighted to announce the further expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our Axiomer technology.
… medicines” The potential of this new technology for RNA therapeutics is immense, says Bart Klein, who was at the … Bart Klein was at the forefront of ProQR's Axiomer® RNAediting technology development. This platform technology …
… USA. ProQR is focused on the development of life changing RNA therapies to meet the unmet need of individuals and … of the communities we serve. Our proprietary Axiomer® RNAediting technology platform enables the editing of …
… USA. ProQR is focused on the development of life changing RNA therapies to meet the unmet need of individuals and … of the communities we serve. Our proprietary Axiomer® RNAediting technology platform enables the editing of …
… USA. ProQR is focused on the development of life changing RNA therapies to meet the unmet need of individuals and … of the communities we serve. Our proprietary Axiomer® RNAediting technology platform enables the editing of …